In patients with advanced liver cirrhosis, the presence of Bifidobacteria as the dominant gut bacteria is associated with higher bacterial diversity, more total bacteria, fewer fungi, and lower...

Pro

Against

Mechanism

Synthesis from 1 study

How it works

When Bifidobacteria are in charge of the gut, they help keep the gut lining strong and stop bad fungi from taking over. This keeps harmful substances from leaking into the blood, which prevents the body from triggering a big inflammatory response. When Enterococcus takes over instead, the gut gets...

Most probable mechanism

In Simple Terms

When Bifidobacteria are abundant in the gut, they help maintain a strong intestinal lining and produce substances that keep harmful fungi in check. This prevents bacteria and fungal parts from leaking into the bloodstream, which stops the immune system from going into overdrive and causing widespread inflammation. In contrast, when Enterococcus dominates, it’s linked to a damaged gut lining, more fungi growing out of control, and a stronger inflammatory response throughout the body.

Causal chain

Bifidobacteria contribute to a higher overall bacterial load and diversity, supporting the production of short-chain fatty acids that nourish intestinal cells and strengthen tight junctions between them.

Verified by multiple studies

which leads to

A robust bacterial community outcompetes fungi for nutrients and space, while also producing antifungal metabolites that suppress the growth of Candida and other fungal species.

Verified by multiple studies

which leads to

Intact intestinal barriers prevent bacterial components and fungal molecules from entering the bloodstream, reducing activation of immune cells in the liver and systemic circulation.

Verified by multiple studies

which leads to

Reduced translocation of microbial products leads to lower activation of immune receptors, resulting in decreased release of pro-inflammatory signaling molecules and markers of immune cell activation.

Verified by multiple studies

Evidence from Studies

Supporting (1)

Community contributions welcome

Distinct clusters of bacterial and fungal microbiota in end-stage liver cirrhosis correlate with antibiotic treatment, intestinal barrier impairment, and systemic inflammation

Cross-Sectional Study

Human

2025 Dec

Contradicting (0)

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

Distinct clusters of bacterial and fungal microbiota in end-stage liver cirrhosis correlate with antibiotic treatment, intestinal barrier impairment, and systemic inflammation

Score: 44

DOI: 10.1080/19490976.2025.2487209

Similar Assertions

In patients with advanced liver cirrhosis, antibiotic use is linked to changes in the gut microbiome, including fewer types of bacteria, a rise in Enterococcus bacteria, and increased Candida fungi.

78%

In people with advanced liver cirrhosis, an imbalance in gut bacteria—specifically high levels of Enterococcus, low bacterial variety, and reduced production of certain bacterial metabolites—is linked to higher levels of a protein that weakens the gut barrier, more widespread inflammation, and more frequent fungal infections.

77%

In people with advanced liver cirrhosis, a decrease in the gut microbes' ability to produce certain metabolic compounds is linked to lower overall microbial numbers and an overgrowth of Enterococcus bacteria, which is associated with increased intestinal barrier damage and systemic inflammation.

77%

In people with advanced liver cirrhosis, an overgrowth of Candida fungi is commonly found alongside bacterial populations dominated by Enterococcus, and this combination is associated with a higher rate of fungal infections, indicating a possible interaction between fungal and bacterial microbes that may worsen clinical outcomes.

73%